Hainan Meihao Xilin Biopharmaceutical

Hainan Meihao Xilin Biopharmaceutical is a clinical-stage biotechnology company based in Haikou, China, focused on developing innovative oncology treatments. As a subsidiary of Hainan Puli Pharmaceutical, the company specializes in the chemical modification of established chemotherapeutic agents to enhance their efficacy and safety. Its lead candidate, MHXL-001, is a novel gemcitabine derivative currently in Phase 1/2 clinical trials for the treatment of advanced solid tumors, specifically pancreatic cancer. The company leverages the strategic location of the Hainan Free Trade Port to accelerate its research and development activities. By focusing on nucleoside analog optimization, Hainan Meihao Xilin aims to provide new therapeutic options for patients with resistant or difficult-to-treat malignancies.